stoxline Quote Chart Rank Option Currency Glossary
  
Palisade Bio, Inc. (PALI)
0.3991  0.004 (0.96%)    03-28 16:00
Open: 0.3953
High: 0.416
Volume: 131,322
  
Pre. Close: 0.3953
Low: 0.389
Market Cap: 5(M)
Technical analysis
2024-03-28 4:53:28 PM
Short term     
Mid term     
Targets 6-month :  0.47 1-year :  0.51
Resists First :  0.4 Second :  0.43
Pivot price 0.37
Supports First :  0.36 Second :  0.29
MAs MA(5) :  0.38 MA(20) :  0.38
MA(100) :  0.51 MA(250) :  0.99
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  53.9 D(3) :  34.2
RSI RSI(14): 49.4
52-week High :  3.65 Low :  0.36
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PALI ] has closed below upper band by 6.6%. Bollinger Bands are 68.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.42 - 0.42 0.42 - 0.42
Low: 0.39 - 0.39 0.39 - 0.39
Close: 0.4 - 0.4 0.4 - 0.4
Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Headline News

Thu, 28 Mar 2024
Palisade Bio, Inc.'s Success on the Line: The Critical Role of Retaining Top Talent Without Safeguards - TipRanks.com - TipRanks

Thu, 28 Mar 2024
Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Down 41.1% in March - Defense World

Wed, 27 Mar 2024
Palisade Bio GAAP EPS of -$1.80 misses by $0.85, revenue of $0.25M (NASDAQ:PALI) - Seeking Alpha

Wed, 27 Mar 2024
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update - GlobeNewswire

Wed, 27 Mar 2024
PALI Stock Earnings: Palisade Bio Beats EPS for Q4 2023 - InvestorPlace

Tue, 26 Mar 2024
Palisade Bio Inc reports results for the quarter ended in December - Earnings Summary - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 12 (M)
Held by Insiders 7.33e+006 (%)
Held by Institutions 1.8 (%)
Shares Short 2,000 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.34e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 360.7 %
Return on Equity (ttm) -50.3 %
Qtrly Rev. Growth 250000 %
Gross Profit (p.s.) 0
Sales Per Share -68.84
EBITDA (p.s.) 0
Qtrly Earnings Growth 0.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.37
Stock Dividends
Dividend 0
Forward Dividend 76760
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android